Health outcomes associated with initiation of basal insulin after 1, 2, or ≥ 3 oral antidiabetes Drug(s) among managed care patients with type 2 diabetes

Medicine & Life Sciences

• Managed Care Programs 93%
• Type 2 Diabetes Mellitus 61%
• Insulin 55%
• Health 39%
• Pharmaceutical Preparations 33%
• Hypoglycemia 15%
• Costs and Cost Analysis 15%
• Drug Prescriptions 9%
• Drug Costs 9%
• Patient Acceptance of Health Care 9%
• Health Resources 9%
• Glycated Hemoglobin A 8%
• Therapeutics 8%
• Global Health 8%
• Hypoglycemic Agents 7%
• Health Care Costs 7%
• Inpatients 6%
• Economics 6%
• Hospitalization 6%
• Health Care Outcome Assessment 5%
• Databases 4%
• Drug Therapy 4%

Social Sciences

• managed care 92%
• chronic illness 80%
• drug 55%
• health 37%
• costs 23%
• Group 19%
• drug therapy 11%
• health care 11%
• clinical outcomes 11%
• health plan 10%
• hospitalization 9%
• medication 6%
• utilization 6%
• event 4%
• resources 3%
• economics 3%
• evidence 3%

Chemical Compounds

• Antidiabetic Agent 100%
• Insulin Derivative 83%
• Hemoglobin 6%
• Drug 3%
• Reduction 3%